International Journal of Nanomedicine (Oct 2022)

Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review

  • Cepero A,
  • Luque C,
  • Cabeza L,
  • Perazzoli G,
  • Quiñonero F,
  • Mesas C,
  • Melguizo C,
  • Prados J

Journal volume & issue
Vol. Volume 17
pp. 5065 – 5080

Abstract

Read online

Ana Cepero,1– 3,* Cristina Luque,1– 3,* Laura Cabeza,1– 3 Gloria Perazzoli,1,2 Francisco Quiñonero,1– 3 Cristina Mesas,1– 3 Consolación Melguizo,1– 3 Jose Prados1– 3 1Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada, 18100, Spain; 2Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, 18071, Spain; 3Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, 18014, Spain*These authors contributed equally to this workCorrespondence: Consolación Melguizo, Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada, 18100, Spain, Tel +34-958-249833, Email [email protected]: The failure of chemotherapeutic treatment in colorectal cancer (CRC), the second most mortal cancer worldwide, is associated with several drug limitations, such as non-selective distribution, short half-life, and development of multiple resistances. One of the most promising strategies in CRC therapy is the development of delivery systems based on nanomaterials that can transport antitumor agents to the tumor site more efficiently, increasing accumulation within the tumor and thus the antitumor effect. In addition to taking advantage of the increased permeability and retention effect (EPR) of solid tumors, these nanoformulations can be conjugated with monoclonal antibodies that recognize molecular markers that are specifically over-expressed on CRC cells. Active targeting of nanoformulations reduces the adverse effects associated with the cytotoxic activity of drugs in healthy tissues, which will be of interest for improving the quality of life of cancer patients in the future. This review focuses on in vitro and in vivo studies of drug delivery nanoformulations functionalized with monoclonal antibodies for targeted therapy of CRC.Keywords: nanoformulation, colon carcinoma, monoclonal antibody, 5-fluorouracil, targeted therapy

Keywords